Drugs / \[89Zr\]Zr-DFO-Girentuximab
\[89Zr\]Zr-DFO-Girentuximab
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07171905 | Feb → Dec 2026 expected | von Hippel-Lindau disease | IRCCS Ospedale San Raffaele | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | \[89Zr\]Zr-DFO-Girentuximab | “Participants VHL disease and in VHL-/- tumors, will receive a single dose of the diagnostic radiopharmaceutical \[89Zr\]Zr-DFO-Girentuximab and subsequently undergo imaging...” NCT07171905 ↗ |
| Modality | Diagnostic / imaging agent | “diagnostic radiopharmaceutical” NCT07171905 ↗ |